GlaxoSmithKline PLC
05 June 2003
Issued - 5th June 2003, London
GlaxoSmithKline plc Announces
Changes to the Board of Directors
GlaxoSmithKline plc (GSK) announces that three new Non-executive Directors are
to join the Board of the company. They are Lawrence Culp, President and CEO of
Danaher Corporation, Crispin Davis, Chief Executive of Reed Elsevier PLC and Sir
Robert Wilson, Chairman of Rio Tinto plc. Mr Culp and Mr Davis will join from
1 July 2003 and Sir Robert from 1 November 2003. Mr Davis will join the
Remuneration Committee.
GSK also announces that Sir Roger Hurn and Paul Allaire have decided to retire
from the Board with immediate effect.
Mr John McArthur will take over the role of Chairman of the Remuneration
Committee from Mr Allaire on an interim basis until a new Chairman of the
Committee is appointed.
Commenting on the changes, Sir Christopher Hogg, Chairman of GSK, said "I am
sorry to lose the services of Sir Roger, who has been a valued colleague. On
behalf of the Board, I would like to thank him warmly for his dedicated and
effective service to the Boards of GSK and Glaxo Wellcome and wish him well for
the future."
"I would also like to thank Paul for his services and contribution to the Boards
of SmithKline Beecham since 1993 and, latterly, GSK. I have always valued Paul's
support and on behalf of the Board wish him well for the future".
"I am delighted that Larry, Crispin and Sir Robert are joining the Board. They
bring with them many years of experience and a track record of success in a
variety of different industries. Their undoubted skills will further strengthen
the Board".
Biographical details of the new Directors and John McArthur are given below.
Simon Bicknell
Company Secretary
5th June 2003
Biographical details
John McArthur
Age 69. A Canadian, John McArthur was appointed as a Non-Executive Director of
Glaxo Wellcome in 1996 and is a former Dean of the Havard Business School. He is
Director of BCE Inc., Cabot Corporation, Rohm and Haas Company and the AES
Corporation. He is also a senior adviser to the President of the World Bank.
Lawrence Culp
Age 40. Mr Culp joined Danaher Corporation in 1990 and after holding
increasingly senior positions was appointed President and CEO in 2001. Prior to
joining Danaher, Mr Culp held positions in Accenture, previously Andersen
Consulting.
Crispin Davis
Age 54. Mr Davis joined Reed Elsevier PLC as Chief Executive in 1999. Prior to
that he was Chief Executive of Aegis Group PLC, which he joined from Guinness
plc, where he was Group Managing Director, United Distillers and a member of the
main board of Guinness plc. Mr Davis spent his early career with Procter &
Gamble.
Sir Robert Wilson
Age 59. Sir Robert joined Rio Tinto plc in 1970 and after holding increasingly
senior positions, including Chief Executive, became Chairman in 1997. He is also
a director of Diageo plc, BG Group plc and the Economist Group. Sir Robert will
step down as Executive Chairman of Rio Tinto plc in October 2003.
Enquiries:
UK Media enquiries: Martin Sutton (020) 8047 5502
David Mawdsley (020) 8047 5502
Chris Hunter-Ward (020) 8047 5502
US Media enquiries: Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
Patricia Seif (215) 751 7709
European Analyst/Investor enquiries: Duncan Learmouth (020) 8047 5540
Anita Kidgell (020) 8047 5542
Philip Thomson (020) 8047 5543
US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002
Tom Curry (215) 751 5419
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.